Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of 1612 Capsules in Treatment of aMnestic Mild Cognitive Impairment: a 52-week, Double Blind,Randomized, Parallel,Placebo Controlled Trial.

NCT02982642 is registered in ClinicalTrials.gov with Dongzhimen Hospital, Beijing as lead sponsor.

NCT NCT02982642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02982642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of 1612 Capsules in Treatment of aMnestic Mild Cognitive Impairment: a 52-week, Double Blind,Randomized, Parallel,Placebo Controlled Trial.
Lead sponsor
Dongzhimen Hospital, Beijing
Phase
Phase 4
Overall status
Withdrawn
Start date
January 31, 2017
Completion date
December 31, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment